Home
/
RIGEL PHARMACEUTICALS INC
/
Financials
/
Quarterly
RIGEL PHARMACEUTICALS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that RIGEL PHARMACEUTICALS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$69.46M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$101.69M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$53.33M
May 6, 2025
Q3
2025
Sep 30, 2024
$55.31M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$36.84M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$29.53M
May 6, 2025
Q3
2024
Sep 30, 2023
$28.13M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$26.89M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$26.07M
May 7, 2024
Q3
2023
Sep 30, 2022
$22.41M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$29.82M
Aug 1, 2023
Q1
2023
Mar 31, 2022
$16.74M
May 2, 2023
Q3
2022
Sep 30, 2021
$21.54M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$26.27M
Aug 2, 2022
Q1
2022
Mar 31, 2021
$81.02M
May 3, 2022
Q3
2021
Sep 30, 2020
$18.39M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$16.02M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$55.76M
May 5, 2021
Q3
2020
Sep 30, 2019
$20.86M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$10.41M
Aug 4, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$4.87M
Nov 6, 2018
Q2
2018
Jun 30, 2018
$1.79M
Aug 8, 2018
Q3
2018
Sep 30, 2017
$900.0K
Nov 6, 2018
Q2
2018
Jun 30, 2017
$3.58M
Aug 8, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$27.90M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$59.61M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$11.45M
May 6, 2025
Q3
2025
Sep 30, 2024
$12.42M
Nov 4, 2025
Q2
2025
Jun 30, 2024
($1.03M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($8.25M)
May 6, 2025
Q3
2024
Sep 30, 2023
($5.69M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($6.60M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($13.54M)
May 7, 2024
Q3
2023
Sep 30, 2022
($19.04M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($13.49M)
Aug 1, 2023
Q1
2023
Mar 31, 2022
($27.45M)
May 2, 2023
Q3
2022
Sep 30, 2021
($20.95M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($13.82M)
Aug 2, 2022
Q1
2022
Mar 31, 2021
$39.50M
May 3, 2022
Q3
2021
Sep 30, 2020
($14.17M)
Nov 2, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$28.42M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$61.10M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$12.77M
May 6, 2025
Q3
2025
Sep 30, 2024
$14.06M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$447.0K
Aug 5, 2025
Q1
2025
Mar 31, 2024
($6.97M)
May 6, 2025
Q3
2024
Sep 30, 2023
($4.47M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($5.27M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($12.73M)
May 7, 2024
Q3
2023
Sep 30, 2022
($18.40M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($12.97M)
Aug 1, 2023
Q1
2023
Mar 31, 2022
($26.26M)
May 2, 2023
Q3
2022
Sep 30, 2021
($19.79M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($13.05M)
Aug 2, 2022
Q1
2022
Mar 31, 2021
$41.76M
May 3, 2022
Q3
2021
Sep 30, 2020
($13.78M)
Nov 2, 2021
Q2
2021
Jun 30, 2020
($17.39M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
$21.03M
May 5, 2021
Q3
2020
Sep 30, 2019
($12.04M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($21.34M)
Aug 4, 2020